Stomach disease is a common ailment, the main cause of which is unhealthy and irregular eating habits and lifestyle
.
With the continuous improvement of people's recognition of proprietary Chinese medicines, the sales scale of the proprietary Chinese medicine stomach medicine market has continued to expand in recent years, and the market potential is huge
.
According to data from Intranet, the total market size of proprietary medicine gastric drugs (gastritis and ulcers) in the six major markets of the three terminals in 2021 has exceeded 10 billion yuan
.
In the first half of 2022, the market sales of proprietary Chinese medicine (gastritis, ulcer) in China's public medical institutions have exceeded 3.
7 billion yuan
.
The sales scale of physical pharmacies is also growing, and it is expected that the market size of proprietary Chinese medicine gastric medicines (gastritis, ulcers) in the terminals of physical pharmacies in Chinese cities will exceed 2.
7 billion yuan
in 2022.
In the face of considerable market space, many domestic pharmaceutical companies are making great efforts to grab food, and the good news of new drugs continues to come
.
For example, in August, Jianmin Pharmaceutical reported that the company submitted a clinical application for Tong Drop granules, which is a class 1.
1 new drug of traditional Chinese medicine, mainly used for the treatment of gastroesophageal reflux disease
.
It is understood that Jianmin Pharmaceutical is actively deploying in the Chinese patent medicine gastric medicine market, and at the end of 2021, the company won the Chinese medicine class 1 new drug Qirui gastric comfort capsules, which is used for mild to moderate chronic non-atrophic gastritis with erosion, moist heat and stasis caused by stomach pain, and the product is also the first gastric medicine class 1 new drug
approved for marketing since the reform of China's review and approval system.
The newly declared clinical granules are the company's second Class 1 new drug in the Chinese proprietary medicine gastric medicine market, which has attracted much market attention
.
News in September, Qingfeng Pharmaceutical's marketing application for olalanti gastric tablets was accepted
by CDE.
It is reported that the new drug is an oral preparation made from the total flavonoside extract extracted from the local medicinal material Citrus aurantium in Jiangxi Province, which is used to treat gastrointestinal dyskinesia functional dyspepsia
.
Qingfeng Pharmaceutical is also actively deploying in the Chinese proprietary medicine gastric medicine market, and has won the production approval of monkey mushroom drink oral liquid, and Ollantic Gastro Kang tablets are expected to become the company's first Class 1 new drug
in this field.
At present, with the continuous progress of the research and development of new proprietary Chinese medicine gastric medicines, the action of proprietary Chinese medicine gastric drugs entering medical insurance has also attracted much attention
from the industry.
In the adjustment of the medical insurance catalogue in 2020, the negotiations between Ganhai Gastric Kang Capsules and Stomach Cleansing Painkiller Pills were successful, and the number of proprietary Chinese medicine gastric medicines in the 2020 and 2021 versions of the national medical insurance catalogue was 109 (by product name).
In the 2021 edition of the medical insurance negotiation catalog, Ganhai gastric kang capsules of Shaanxi Dongke Pharmaceutical, a subsidiary of Jichuan Pharmaceutical, and stomach clearing and pain-relieving pills of Jilin Huakang Pharmaceutical (a subsidiary of Changchun High-tech) are included in
the catalog.
According to data from Intranet, at the terminals of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions), the sales growth rate of these two drugs has been increasing in recent years, of which Ganhai Gastrokang capsules increased from 4.
6% in 2020 to 14.
8% in 2021, and the growth rate in the first half of 2022 was more than 148%.
The sales growth rate of gastric pain-relieving pills was -12.
4% in 2020, close to 160% in 2021, and more than 294%
in the first half of 2022.
The National Health Insurance Administration recently announced the results
of the expert review of the adjustment of the national medical insurance catalogue in 2022.
According to preliminary statistics, 344 drugs have passed the preliminary examination, including Qirui gastric comfort capsules
.
Jianmin Pharmaceutical Group recently said in response to investor inquiries that Qirui gastric comfort capsules have been sold in some provinces and regions, but the sales volume is small
.
If the product successfully enters the medical insurance, it may usher in a high-speed increase and the potential can be expected
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
